⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18656033 | 0.78 | PIK3CD (0.43) | — | |
| SCHEMBL24923605 | 0.75 | — | — | |
| SCHEMBL117132 | 0.73 | — | — | |
| SCHEMBL221000 | 0.73 | — | — | |
| SCHEMBL590804 | 0.73 | — | — | |
| SCHEMBL9498340 | 0.73 | — | — | |
| SCHEMBL15241818 | 0.73 | — | — | |
| SCHEMBL28823346 | 0.73 | — | — | |
| SCHEMBL796728 | 0.73 | — | — | |
| SCHEMBL1840979 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997656-B | Substituted indole compounds useful as TLR7/8/9 inhibitors | 百时美施贵宝公司 | 2023-04-14 | — | — | CN | claimed |
| EP-3724183-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-21 | — | — | EP | claimed |
| WO-2019118799-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-20 | — | — | WO | claimed |
| CN-119841769-A | Preparation method, intermediate and application of 1-alkylpyridin-2-ketone compound | 上海凌凯科技股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240025858-A1 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4269399-A1 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
| CN-1166169-A | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors | SANKYO CO (JP) | 1997-11-26 | — | — | CN | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |